Bristol Myers: positive long-term data in CMHo

(CercleFinance.com) - Bristol Myers Squibb reports further positive long-term follow-up data from the EXPLORER-LTE cohort of the MAVA-LTE Phase III study, evaluating its Camzyos in adults with symptomatic hypertrophic obstructive cardiomyopathy (OHMC).


Cumulative analysis of data up to 3.5 years showed consistent and sustained improvements in echocardiographic measures and symptoms, with no new safety signals observed, the pharmaceutical company summarizes.

These data, presented at the European Society of Cardiology (ESC) Congress in London, underline the established efficacy and safety profile of Camzyos, the first and only approved cardiac myosin inhibitor targeting the source of CMHo.


Copyright (c) 2024 CercleFinance.com. All rights reserved.